BRIEF—ICER Draft Evidence Report on obeticholic acid for NASH

US health technology assessor the Institute for Clinical and Economic Review (ICER) has now released a Draft Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis (NASH).

This preliminary draft marks the midpoint of the ICER’s process of assessing these treatments, and the findings within the document should not be interpreted to be the Institute’s final conclu0.       klsions.

To enable clinical experts and patient advocates to respond to the COVID-19 pandemic,  ICER has expanded the timeframe for this assessment, and this draft report will now be open to public comment until June 24, 2020.

Based on this stakeholder feedback, the ICER may revise key assumptions and findings for its Evidence Report. That revised Evidence Report will be subject to deliberation during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees, on a date to be determined.